Introduction

The fourth original paper is entitled GLP1 receptor agonist therapy with and without SGLT inhibitors in patients with type 2 diabetes. Abigutite significantly reduced the rate of the primary composite outcome but most importantly 575 participants or 6% were treated with LGLT2 inhibitors at best line. The effect of effetretinite on cardiovascular outcomes included 618 patients or 15% also receiving SGLT2 inhibitor. With all patients treated with albicutite.